Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.49 |
| ▸ | KDM1A | O60341 | 5/20 | 0.44 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002842 | 1.00 | PDE4B (0.49) | PDE4BKDM1ATRPM5APPLTB4R | |
| SCHEMBL30394598 | 1.00 | PDE4B (0.49) | PDE4BKDM1ATRPM5APPLTB4R | |
| SCHEMBL17002809 | 0.85 | ALDH1A1 (0.41) | PDE4BKDM1A | |
| SCHEMBL17002812 | 0.85 | ALDH1A1 (0.41) | PDE4BKDM1A | |
| SCHEMBL25289489 | 0.84 | CA1 (0.46) | PDE4BKDM1AAPP | |
| SCHEMBL30457311 | 0.84 | CA1 (0.46) | PDE4BKDM1AAPP | |
| SCHEMBL17003034 | 0.83 | KDM1A (0.48) | PDE4BKDM1ATRPM5APPLTB4R | |
| SCHEMBL17003032 | 0.83 | KDM1A (0.48) | PDE4BKDM1ATRPM5APPLTB4R | |
| SCHEMBL17002757 | 0.81 | KDM1A (0.56) | PDE4BKDM1A | |
| SCHEMBL17002758 | 0.81 | KDM1A (0.56) | PDE4BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2907802-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | BHMT, HNMT, KDM1A | PDE4B 1570/4885KDM1A 3/4885TRPM5 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.